Johnson & Johnson's Invokana is alone in the class of SGLT2 diabetes drugs in carrying a boxed warning detailing amputation risks, but a new real-world analysis of more than 700,000 patients found the medication and other SGLT2 drugs lowered heart failure hospitalizations without increasing those risks.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,